Package Leaflet: Information for the User
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets EFG
Lamivudine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
|
Contents of the pack:
Lamivudine Teva Pharma B.V. is used in the treatment of HIV infection in adults and children.
The active substance of Lamivudine Teva Pharma B.V. is lamivudine. Lamivudine Teva Pharma B.V. is a type of medicine known as an antiretroviral. It belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Lamivudine Teva Pharma B.V. does not completely cure HIV infection, it reduces the amount of virus in the body and keeps it at a low level. It also increases the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that plays an important role in helping your body to fight infection.
Not everyone responds to treatment with Lamivudine Teva Pharma B.V. in the same way. Your doctor will monitor the effectiveness of your treatment.
Do not take Lamivudine Teva Pharma B.V.
Consult your doctorif you think this applies to you.
Warnings and precautions
Consult your doctor or pharmacist before you start taking Lamivudine Teva Pharma B.V.
Some people who take Lamivudine Teva Pharma B.V. or other combination treatments for HIV infection have a higher risk of serious side effects. You need to know that there is a higher risk:
Consult your doctorif you are affected by any of these conditions. You may need to have extra checks, such as blood tests, while you are taking this medicine For more information see section 4.
Be aware of important symptoms
Some people who take medicines for HIV infection develop other conditions that can be serious. You need to know about the signs and symptoms to look out for while you are taking Lamivudine Teva Pharma B.V.
Read the information under “Other possible side effects of combination therapy for HIV” in section 4 of this leaflet.
Protect others
HIV infection is spread by having sex with someone who is infected or by transfer of infected blood (for example, by sharing injection needles). While you are taking this medicine you may still transmit HIV to others, even if you are taking antiviral effective treatment that reduces the amount of virus in your blood.
Consult your doctor about the precautions you need to take to avoid infecting others.
Other medicines and Lamivudine Teva Pharma B.V.
Tell your doctor or pharmacistif you are taking, have recently taken or might take any other medicines.
Remember to tell your doctor or pharmacist if you start taking any new medicines while you are taking Lamivudine Teva Pharma B.V.
The following medicines must not be taken with Lamivudine Teva Pharma B.V.:
Tell your doctorif you are being treated with any of these medicines.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Lamivudine Teva Pharma B.V. and similar medicines may harm your unborn child. If you have taken Lamivudine Teva Pharma B.V. during your pregnancy, your doctor may request that you have regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.
Women with HIV infection should not breastfeed their babiesbecause HIV infection can be passed on to the baby through breast milk.
A small amount of the ingredients of Lamivudine Teva Pharma B.V. can also pass into breast milk.
If you are breastfeeding, or think you might want to breastfeed: consult your doctor immediately.
Driving and using machines
Lamivudine Teva Pharma B.V. is unlikely to affect your ability to drive or use machines.
Lamivudine Teva Pharma B.V. contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, i.e., essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you.Check with your doctor or pharmacist if you are not sure.
Swallow the tablets with a little water. Lamivudine Teva Pharma B.V. can be taken with or without food.
If you are unable to swallow the tablets whole, you can break them and mix with a small amount of food or drink; take the whole dose immediately.
Keep in regular contact with your doctor
Lamivudine Teva Pharma B.V. helps to control your condition. You must take it every day to control your HIV infection. You may still develop other infections and illnesses associated with HIV infection.
Stay in touch with your doctor and do not stop taking Lamivudine Teva Pharma B.V.without discussing it with your doctor first.
The recommended dose is
Adults, adolescents and children weighing at least 25 kg
The usual dose is one 300 mg tablet once daily.
Lamivudine Teva Pharma B.V. is also available as 150 mg tablets for the treatment of children from 3 months of age and weighing less than 25 kg.
It is also available as an oral solution for the treatment of children over 3 months of age and for patients who are unable to take tablets or who require a dose adjustment.
If you or your child have kidney problems, your dose may need to be adjusted.
Consult your doctorif this applies to you or your child.
If you take more Lamivudine Teva Pharma B.V. than you should
If you take more Lamivudine Teva Pharma B.V. than you should, contact your doctor or pharmacist, or go to the nearest hospital emergency department for more information. If possible, show them the Lamivudine Teva Pharma B.V. pack.
If you forget to take Lamivudine Teva Pharma B.V.
If you forget to take a dose, take it as soon as you remember and then continue with your treatment as usual.
Do not take a double dose to make up for a forgotten dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During HIV treatment, weight and levels of blood sugars and fats may increase. This is partly due to a return to better health and partly due to the treatment itself. Your doctor will monitor these changes.
When you are being treated for HIV, it can be difficult to tell whether a symptom is a side effect of Lamivudine Teva Pharma B.V. or other medicines you are taking, or a result of the HIV infection itself. Therefore, it is very important that you inform your doctor about any changes in your health.
In addition to the side effects listed below for Lamivudine Teva Pharma B.V., other conditions can develop during combination therapy for HIV.
It is important that you read the information under the heading “Other possible side effects of combination therapy for HIV”.
Common side effects
May affect up to 1 in 10people:
Uncommon side effects
May affect up to 1 in 100people:
Uncommon side effects that may show up in blood tests are:
Rare side effects
May affect up to 1 in 1,000people:
A rare side effect that may show up in blood tests is:
Very rare side effects
May affect up to 1 in 10,000people:
A very rare side effect that may show up in blood tests is:
If you experience any side effects
Tell your doctor or pharmacistif you experience any side effects, even if they are not listed in this leaflet.
Other possible side effects of combination therapy for HIV
Combination therapy for HIV, such as Lamivudine Teva Pharma B.V., can cause other conditions to develop during HIV treatment.
Worsening of previous problems
People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably due to the improvement in the body's natural defence (immune) system, which enables the body to fight these infections.
In addition to opportunistic infections, autoimmune disorders (a condition where the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms such as muscle weakness, weakness in the hands and feet that gradually spreads to the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately for further evaluation and treatment.
If you notice any symptoms of infection while you are taking Lamivudine Teva Pharma B.V.:
Tell your doctor immediately. Do not take any other medicines for the infection without your doctor's advice.
You may have problems with your bones
Some patients taking combination therapy for HIV develop a condition called osteonecrosis. In this condition, parts of the bone tissue die because the bone is no longer receiving sufficient blood. People have a higher risk of getting this condition:
Signs of osteonecrosis include:
If you notice any of these symptoms: tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Lamivudina Teva Pharma B.V.
Tablet core: Microcrystalline cellulose, sodium starch glycolate, magnesium stearate. Film coating: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, yellow iron oxide (E172), black iron oxide (E172)
Appearance and Packaging of the Product
Gray tablet, rhomboid in shape, biconvex, film-coated, engraved with "L 300" on one side and smooth on the other.
Lamivudina Teva Pharma B.V. is available in aluminum blisters containing 20, 30, 60, 80, 90, 100, and 500 tablets or HDPE containers containing 30 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer
Teva Pharmaceutical Works Private Limited Company
Pallagi út 13
Debrecen H-4042
Hungary
Pharmachemie B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium Teva Pharma Belgium N.V./S.A. /AG Tel: +32 3 820 73 73 | Lithuania UAB Teva Baltics Tel: +370 5 266 02 03 |
Bulgaria Teva Pharmaceuticals EAD Tel: +359 2 489 95 85 | Luxembourg ratiopharm GmbH Germany Tel: +49 731 402 02 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 1 288 64 00 |
Denmark Teva Denmark A/S Tel: +45 44 98 55 11 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Germany ratiopharm GmbH Tel: +49 731 402 02 | Netherlands Teva Nederland B.V. Tel: +31 800 0228400 |
Estonia UAB Teva Baltics Eesti filiaal Tel: +372 6610801 | Norway Teva Norway AS Tel: +47 66 77 55 90 |
Greece Specifar A.B.E.E. Tel: +30 2118805000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 970070 |
Spain Teva Pharma, S.L.U. Tel: +34 91 387 32 80 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 22 345 93 00 |
France Teva Santé Tel: +33 1 55 91 7800 | Portugal Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 21 476 75 50 |
Croatia Pliva Hrvatska d.o.o. Tel: +385 1 37 20 000 Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Romania Teva Pharmaceuticals S.R.L Tel: +4021 230 65 24 Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland Teva Pharma Iceland ehf. Tel: +354 5503300 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 2 5726 7911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva Finland Oy Tel: +358 20 180 5900 |
Cyprus Specifar A.B.E.E. Greece Tel: +30 2118805000 | Sweden Teva Sweden AB Tel: +46 42 12 11 00 |
Latvia UAB Teva Baltics filiale Latvija Tel: +371 67323666 | United Kingdom Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of the Last Revision of this Leaflet: January 2022
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu/.